Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes

Breast Cancer Clinical Trial

Official title:

Hypofractionated, Comprehensive Radiation Therapy for Node-Positive Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02700386
• Other study ID #: 15-1329.cc
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 11, 2016
• Est. completion date: March 2025

Study information

• Verified date: September 2023
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study is being done to learn more about a particular dose of radiation treatment for breast cancer that is completed in a shorter amount of time than what has traditionally been used to treat breast cancer. Subjects are being asked to be in this research study because they have already had surgery for breast cancer and some cancer cells were found in their lymph nodes that drain the breast tissue.

Description:

Subjects who join the study will receive a shortened course of radiation treatment that will last approximately four (4) weeks, instead of the traditional six (6) week course that women have typically received in this situation. The shorter course subjects will receive is designed in a way that it is thought to be equivalent to the longer course. This shorter course has already been shown to be very safe and effective when treating breast cancer in the breast tissue only. However, because cancer cells were found in the lymph nodes that drain their breast, subjects require radiation to a larger area of their chest, armpit, and shoulder than has been completely tested with this experimental dose.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 112
• Est. completion date: March 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 101 Years

Eligibility

Inclusion Criteria:

1. Adult women (=18 years old) with breast cancer who have undergone surgery for their primary breast tumor (either lumpectomy or mastectomy +/- reconstruction) and are confirmed to have involved lymph nodes on surgical pathology.

2. Patient who have undergone either a total mastectomy or a lumpectomy are eligible.

Acceptable procedures for assessment of axillary nodal status at the time of surgery include:

• axillary node dissection;

• sentinel node biopsy alone; or

• sentinel node biopsy followed by axillary node dissection.

3. Eligible women include AJCC (American Joint Committee on Cancer) 7th ed. Stage cN0 or cN1 subsequently staged after surgery as Stage pIB (N1mic), pIIA, pIIB, pIIIA, pIIIB, or N3a (10 or more axillary nodes) only: note that ypN0 will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node-negative at the time of surgery. Note that women less than 50 years of age, women who received chemotherapy, patients staged as pN0 (i+ or mol+), and large-breasted women are eligible for enrollment.

4. The patient must have recovered from surgery with the incision completely healed and no signs of infection. If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may interfere with delivery of radiation therapy should have resolved. The patient must have an ECOG performance status of 0 or 1 (KPS >70%).

5. The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 180 days if chemotherapy is not delivered adjuvantly. If adjuvant chemotherapy was administered, the interval between the last chemotherapy treatment and randomization must be no more than 180 days.

6. Before the patient is enrolled, the consent form, including any addenda, must be signed and dated by the patient and the person who explains the study to that patient.

7. Subjects will have the ability to understand, and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. patients <18 years old

2. pregnant women

3. male patients

4. women with T4 disease, including inflammatory breast cancer

5. women who have declined or otherwise not received preceding surgery

6. women with positive margins after primary surgery

7. women with node-negative disease

8. women without histologic confirmation of nodal involvement

9. women more than 180 days out from primary breast surgery or adjuvant chemotherapy

10. patients with clinically detected or suspicious lymph node involvement not readily amenable to surgical treatment (=cN2 disease)

11. patients with synchronous bilateral breast cancers

12. patients with prior ipsilateral thoracic or breast radiation

13. patients with distant metastatic disease (cM1) or a life expectancy of less than 5 years

14. active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma.

15. other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.

16. patients with psychiatric or addictive disorders or other conditions that, in the opinion of the Investigator, would preclude the patient from meeting the study requirements.

17. patients with a separate non-cutaneous cancer diagnosis for which the patient has not been without evidence of disease for at least 5 years.

Note: women <50 years of age, women who received chemotherapy, pN0 (i+ or mol+), and large-breasted women are eligible for enrollment.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Combination Product:
• Adjuvant Hypofractionated Radiation
Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.

Locations

Country	Name	City	State
United States	University of Colorado Hospital	Aurora	Colorado
United States	Memorial Hospital	Colorado Springs	Colorado
United States	Poudre Valley Hospital	Fort Collins	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03	Any grade of 4 or 5 toxicity by CTCAE will qualify as a serious adverse event (SAE). Brachial plexopathy Grade 2 ('moderate symptoms; limiting instrumental activity of daily living (ADL)') or Grade 3 ('severe symptoms; limiting self-care ADL') and Grade 3 lymphedema ('Severe symptoms; limiting self-care ADL') and Grade 2 pneumonitis (requires steroids) will qualify as reportable adverse events (AE).	Up to 60 months
Primary	Number of participants with lymphedema severity by measuring interlimb circumference	An increase in interlimb arm circumference of at least 10% in the lower arm or the upper arm, or both, compared with the contralateral arm at the same timepoint, will be judged to be clinically significant lymphedema. Arm circumference 15 cm above the medial epicondyle (upper arms) and 15 cm below the medial epicondyle (lower arms) will be measured every 6 months, up to 60 months	Up to 60 Months
Primary	Number of participants with symptomatic rib fracture as measured by plain film or CT	Symptomatic rib fracture will be diagnosed by evidence of a correlative lesion on plain film or CT.	Up to 60 Months
Primary	Number of participants with new development of ischemic heart disease as measured by EKG	Ischemic heart disease will be measured by the new development of angina with corresponding EKG changes, or myocardial infraction.	Up to 60 Months
Primary	Number of participants reporting shoulder stiffness as measured by the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C3014) and breast-cancer module (BR23)	Reported by the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C3014) and breast-cancer module (BR23).	Up to 60 Months
Secondary	Number of participants with disease recurrence	Recurrent disease presentation within axillary lymph node levels I, II, or III. The supraclavicular region is not included in this endpoint.	Up to 60 months
Secondary	Number of participants with metastasis-free survival	Measured by the time from date of enrollment to earlier of clinical detection of metastatic disease beyond the breast/chestwall and regional lymph nodes or death.	Up to 60 months
Secondary	Number of participants with local-regional failure free survival	Measured by the time from date of enrollment to earlier of clinical detection of any ipsilateral recurrent disease to the breast/chestwall or regional lymph nodes (levels I, II, III, supraclavicular, and internal mammary lymph nodes) or death.	Up to 60 months
Secondary	Number of participants with a change in quality of life score as measured by the EORTC QLQ-C3014 and breast-cancer module (BR23)	Patient's quality of life from pre-treatment to post-treatment, reported by the quality of life questionnaire [EORTC QLQ-C3014 and breast-cancer module (BR23)].	Up to 60 months